Bionure

About:

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Website: http://www.bionure.com/

Twitter/X: Bionure

Top Investors: Capital Cell, Alta Life Sciences, Hugo Peris

Description:

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Total Funding Amount:

5.07M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Menlo Park, California, United States

Founded Date:

2009-10-01

Contact Email:

info(AT)bionure.com

Founders:

Albert Zamora, Pablo Villoslada

Number of Employees:

1-10

Last Funding Date:

2018-05-17

IPO Status:

Private

Industries: